OG article by Andrew Bowen December 29, 2025 San Diego's cannabis business tax increase from 8% to 10% failed to meet revenue expectations, generating $19.7 million this fiscal year against a projected $21.3 million, a $1.5 million shortfall. Last year at 8%, it yielded $16.7 million, up from $16.7 million at 5% in 2016. The Independent Budget Analyst attributes the gap to declining taxable receipts from illegal market competition, oversupply lowering wholesale prices, and c

OG article by Anthony Martinelli December 29, 2025 A national survey by JL Partners, conducted among 1,000 registered voters on December 20-21, 2025, revealed that 53% of Americans support legalizing marijuana nationwide. Support reached 62% among Democrats and 51% among Republicans, indicating a shift in opinion across party lines. By gender, 58% of men favored legalization compared to 50% of women. Age demographics showed the highest support at 61% for those aged 30-49, wi

OG article by Emma Burch December 29, 2025 Oklahoma has implemented new medical marijuana regulations effective in 2026 and late 2025 to enhance safety and oversight. Under Senate Bill 1066, starting January 1, 2026, doctors must complete an initial education course and register with the Oklahoma Medical Marijuana Authority to prescribe marijuana; previously, an active license from relevant state boards sufficed, and non-compliant doctors will lead to rejected patient applic

OG article by Dan Chalk December 29, 2025 A Michigan State University study reveals that at least one in six pregnant women in Michigan use marijuana during pregnancy, with results published in the January 2026 issue of Addiction. The research, led by epidemiologist Ban Al-Sahab, used urine samples to track cannabis use among expectant mothers statewide and found unmarried women twice as likely as married women to use it, alongside higher rates among those with less educatio

OG article by Charles Gasparino December 29, 2025 President Donald Trump's executive order on December 18, 2025, reclassified marijuana from a Schedule-1 to a Schedule-3 controlled substance, aiming to facilitate banking for the $60 billion cannabis industry. The industry celebrated, expecting access to services from major banks like JPMorgan, Bank of America, and Citigroup, which had previously avoided cannabis businesses due to federal regulations. However, bank executives

OG article by Nathaniel Weixel December 29, 2025 President Trump's executive order, issued last week, directs the expedited rescheduling of marijuana from Schedule I to Schedule III and introduces Medicare coverage for CBD, potentially aiding the hemp industry amid a looming ban. This follows a November government funding bill provision that closes a loophole in the 2018 farm bill, reclassifying hemp-derived products with over 0.4 milligrams of THC as cannabis, effective nex

OG article by Anthony Martinelli December 26, 2025 An observational study followed 137 new medical marijuana patients in Pennsylvania over one year, assessing sleep quality via the Pittsburgh Sleep Quality Index. Participants completed surveys at baseline and 3, 6, 9, and 12 months. Global sleep scores improved significantly from baseline to the first follow-up, with gains sustained throughout the year without further progression. Subscales reflected consistent benefits in l

OG article by Anthony Martinelli December 26, 2025 A study in the Journal of Ethnopharmacology examined cannabidiol (CBD)'s hepatoprotective effects in a mouse model of acute liver injury induced by lipopolysaccharide and D-galactosamine. Chinese researchers administered CBD at 2.5 and 5 mg/kg doses. Treatment markedly lowered serum markers of liver damage, including alanine and aspartate aminotransferase. Histopathology showed reduced tissue injury, while assays revealed de

OG article by Anthony Martinelli December 26, 2025 President Trump issued an executive order directing Attorney General Pam Bondi to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, targeting completion by January 2026 end. The order mandates coordination with Health and Human Services, building on their 2023 recommendation. It emphasizes adhering to federal law while avoiding delays in rulemaking. Rescheduling would

OG article by Anthony Martinelli December 26, 2025 A recent study in Archives of Biochemistry and Biophysics explored CBD-loaded biohybrid micelles for enhanced anti-cancer activity in colon cancer. Researchers from East China University of Science and Technology developed micelles using polyethylene glycol, chitosan, bile acid, and quercetin to overcome CBD's poor solubility, low bioavailability, and non-targeted distribution. In vitro tests on HCT116, HT29, and Caco-2 colo

OG article by University of California - Los Angeles Health Sciences December 26, 2025 A comprehensive review published in JAMA Psychiatry analyzed over 2,500 studies on medical cannabis from 2010 to 2025, prioritizing 120 high-quality randomized clinical trials, meta-analyses, and guidelines. Researchers found substantial evidence gaps for most claimed benefits, despite widespread public use for conditions like chronic pain, anxiety, and insomnia. A 2018 survey indicated 27

OG article by Shaun Salvaje December 26, 2025 According to a filing submitted to the Texas Secretary of State, the Executive Commissioner of the Texas Health and Human Services Commission—on behalf of the Department of State Health Services—has proposed amendments to Title 25, Chapter 300, the rules governing the manufacture, distribution, and retail sale of consumable hemp products in Texas. These rules trace back to House Bill 1325, which created Texas Health and Safety Cod